2018
DOI: 10.1007/s00432-018-2656-y
|View full text |Cite
|
Sign up to set email alerts
|

Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy

Abstract: PurposeEfficacy and the frequency of tumor cavitation have not been investigated in patients with metastatic colorectal cancer (mCRC) and lung metastases (LMs) treated with chemotherapy in combination with bevacizumab. This study was aimed to evaluate the efficacy and safety of bevacizumab for unresectable mCRC with LM and to determine the frequency of tumor cavitation, and its correlation with clinical outcomes in patients receiving bevacizumab plus chemotherapy.MethodsPatients with mCRC and LMs treated with … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2018
2018
2025
2025

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 30 publications
0
7
0
Order By: Relevance
“…It is the third most common cancer and second leading cause of cancer death in US. Since the introduction of anti-angiogenic agents, there has been significant interest in understanding the molecular basis of angiogenesis in CRC and the discovery of potent agents with the capability of inhibiting the angiogenesis pathway [1][2][3][4][5][6][7][8][9].…”
Section: Introductionmentioning
confidence: 99%
“…It is the third most common cancer and second leading cause of cancer death in US. Since the introduction of anti-angiogenic agents, there has been significant interest in understanding the molecular basis of angiogenesis in CRC and the discovery of potent agents with the capability of inhibiting the angiogenesis pathway [1][2][3][4][5][6][7][8][9].…”
Section: Introductionmentioning
confidence: 99%
“…Peng et al described that bevacizumab treatment for lung metastasis of colon cancer resulted in lung cavitation in 20% of patients. In case that lung cavitation occurred, the OS was significantly better, but not the PFS (18). Thus, although cavitation of lung tumors (primary and metastatic) treated with antiangiogenic agents may be an indicator of a favorable prognosis, further studies are needed.…”
Section: Discussionmentioning
confidence: 99%
“…Bevacizumab is a human monoclonal antibody against vascular endothelial growth factor (VEGF), and is the first Food and Drug Administration (FDA) approved angiogenesis inhibitor. Bevacizumab combination chemotherapy for advanced metastatic CRC has achieved a good therapeutic effect in clinical research results, but its safety and effectiveness in pregnant patients require further evaluation (15,16).…”
Section: Discussionmentioning
confidence: 99%